NASDAQ:ITOS - iTeos Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.33
  • Forecasted Upside: 172.81 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$17.35
▲ +0.78 (4.71%)

This chart shows the closing price for ITOS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New iTeos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ITOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ITOS

Analyst Price Target is $47.33
▲ +172.81% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for iTeos Therapeutics in the last 3 months. The average price target is $47.33, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 172.81% upside from the last price of $17.35.

This chart shows the closing price for ITOS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in iTeos Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2022Piper SandlerLower Price Target$42.00 ➝ $34.00High
12/13/2021HC WainwrightBoost Price TargetBuy ➝ Buy$37.00 ➝ $54.00High
11/12/2021SVB LeerinkLower Price TargetOutperform$55.00 ➝ $54.00High
11/11/2021Piper SandlerLower Price TargetOverweight$50.00 ➝ $42.00High
8/13/2021SVB LeerinkLower Price TargetOutperform$56.00 ➝ $55.00Medium
5/19/2021SVB LeerinkLower Price TargetOutperform$60.00 ➝ $45.00High
5/5/2021HC WainwrightInitiated CoverageBuy$37.00High
4/6/2021SVB LeerinkBoost Price TargetOutperform$37.00 ➝ $60.00High
3/25/2021WedbushBoost Price TargetOutperform$46.00 ➝ $52.00Medium
11/19/2020SVB LeerinkBoost Price TargetOutperform$36.00 ➝ $37.00Low
10/7/2020Robert W. BairdInitiated CoverageOutperform$45.00Low
8/18/2020JPMorgan Chase & Co.Initiated CoverageOverweight$40.00High
8/18/2020SVB LeerinkInitiated CoverageOutperform$36.00High
8/18/2020WedbushInitiated CoverageOutperform$45.00High
8/18/2020Piper SandlerInitiated CoverageOverweight$50.00High
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/27/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2022
  • 2 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
5/26/2022

Current Sentiment

  • 2 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
iTeos Therapeutics logo
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $17.35
Low: $16.58
High: $17.55

50 Day Range

MA: $28.26
Low: $16.57
High: $37.00

52 Week Range

Now: $17.35
Low: $16.21
High: $52.43

Volume

340,104 shs

Average Volume

520,404 shs

Market Capitalization

$616.64 million

P/E Ratio

2.22

Dividend Yield

N/A

Beta

1.94

Frequently Asked Questions

What sell-side analysts currently cover shares of iTeos Therapeutics?

The following Wall Street analysts have issued research reports on iTeos Therapeutics in the last twelve months: HC Wainwright, Piper Sandler, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for ITOS.

What is the current price target for iTeos Therapeutics?

0 Wall Street analysts have set twelve-month price targets for iTeos Therapeutics in the last year. Their average twelve-month price target is $47.33, suggesting a possible upside of 172.8%.
View the latest price targets for ITOS.

What is the current consensus analyst rating for iTeos Therapeutics?

iTeos Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ITOS will outperform the market and that investors should add to their positions of iTeos Therapeutics.
View the latest ratings for ITOS.

How do I contact iTeos Therapeutics' investor relations team?

The company's listed phone number is 339-217-0161 and its investor relations email address is [email protected] The official website for iTeos Therapeutics is www.iteostherapeutics.com. Learn More about contacing iTeos Therapeutics investor relations.